Eisai Draws U.S. FDA Warning Letter For Misleading Efficacy and Safety Claims
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - U.S. FDA issued a warning letter to Eisai for "serious" violations regarding a Dacogen (decitabine) marketing document that minimize risk and "greatly overstates the efficacy of Dacogen.